Listed by the USPTO as COPPINS, JANET L
Tech Center 1600 • Art Units: 1617 1621 1625 1626 1628 1657 1672
This examiner grants 73% of resolved cases
Janet L. Coppins examines cases in Art Unit 1617 of Tech Center 1600. She has 933 resolved cases and an allowance rate of 72.6%. The median days to allowance is 848. These figures reflect a high volume of experience and a relatively high probability of success for applicants, combined with an efficient timeline for case resolution.
The interview lift is 26.1%, suggesting that interviews are an effective strategy for this examiner. This positive lift indicates that direct communication can help resolve outstanding rejections and improve the probability of reaching an allowance. Practitioners should consider requesting an interview as a standard part of their prosecution strategy to advance their applications.
Top companies include Bristol-Myers Squibb Company, Fujifilm Corporation, and Dana-Farber Cancer Institute Inc. Firms like Meunier Carlin & Curfman LLC, Acuity Law Group, P.C., and BALLARD SPAHR LLP are active. These firms have experience navigating the specific prosecution landscape of Art Unit 1617 and the examiner's requirements for patentability.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17712527 | PHARMACEUTICAL COMPOSITION AND KIT CONTAINING NOVEL PENAM DERIVATIVE OR SALT THEREOF AND ONE OR MORE COMPOUNDS SELECTED FROM beta-LACTAMASE INHIBITORY COMPOUND AND ANTIBACTERIAL COMPOUND OR SALTS THEREOF | Final Rejection | FUJIFILM Corporation |
| 18553999 | PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | Final Rejection | Bristol-Myers Squibb Company |
| 18553988 | TRANSCRIPTIONAL ENHANCED ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | Final Rejection | Dana-Farber Cancer Institute, Inc. |
| 18550996 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | Non-Final OA | Vanderbilt University |
| 17548915 | PREVENTION OF PRETERM BIRTH (PTB) BY INHIBITION OF FKBP51 | Non-Final OA | UNIVERSITY OF SOUTH FLORIDA |
| 18428639 | Methods for Restoring Sensitivity to TTFields in TTFields-Resistant Cancer Cells with PTGER3 Inhibitors | Final Rejection | Novocure GmbH |
| 18558364 | METHOD OF SYNTHESIZING DENDRIMERIC AMPHIPHILE | Non-Final OA | KAOHSIUNG MEDICAL UNIVERSITY |
| 17432158 | PHARMACEUTICAL COMPOSITION AND THERAPEUTIC METHOD FOR TREATING FGFR1 VARIANT-POSITIVE BRAIN TUMOR | Final Rejection | TAIHO PHARMACEUTICAL CO., LTD. |
| 18552683 | A PORPHYRIN COMPOSITION AND PROCESS OF PRODUCING THE PORPHYRIN COMPOSITION | Non-Final OA | Novomer LLC |
| 18570727 | (R)-N-ETHYL-5-FLUORO-N-ISOPROPYL-2-((5-(2-(6-((2-METHOXYETHYL)(METHYL)AMINO)-2-METHYLHEXAN-3-YL)-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-1,2,4-TRIAZIN-6-YL)OXY)BENZAMIDE BESYLATE SALT | Non-Final OA | Janssen Pharmaceutica NV |
| 18456744 | COMPOSITION FOR INCREASING MUSCLE | Non-Final OA | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy72.6% of resolved applications examined by Janet L Coppins were allowed (933 resolved cases), compared with 34.1% across Art Unit 1617 over the last five years.
This examiner's interview lift is +26.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Janet L Coppins took 848 days on average from filing to allowance.
Janet L Coppins examines applications in Art Unit 1617 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
